Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use VRAYLAR safely and effectively. See full prescribing information for VRAYLAR . VRAYLAR ® ( cariprazine ) c apsules , for o ral u se Initial U.S. Approval: 2015
Medication labelWhy this: Advisory · dailymed-prescription
VRAYLAR® is indicated for: • Treatment of schizophrenia in adult and pediatric patients 13 years of age and older [see Clinical Studies ( 14.1 )] • Acute treatment of manic or mixed episodes associated with bipolar I disorder in adult and pediatric patients 10 years of age and older [see Clinical Studies ( 14.2 )] • Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adult patients [see Clinical Studies ( 14.3 )] • Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adult patients [see Clinical Studies ( 14.4 )]
- generic_name
- cariprazine
- product_names
- cariprazine
- ndc
- 61874-250, 61874-250-30, 61874-275, 61874-275-30, 61874-115, 61874-115-30, 61874-115-90, 61874-115-11, 61874-115-20, 61874-115-17, 61874-115-07, 61874-115-31, 61874-130, 61874-130-30, 61874-130-90, 61874-130-11, 61874-130-20, 61874-130-07, 61874-130-31, 61874-145, 61874-145-30, 61874-145-90, 61874-145-07, 61874-160, 61874-160-30, 61874-160-90, 61874-160-07, 61874-170, 61874-170-08
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en